 RALEIGH, NC ACCESSWIRE May 17, 2021 9 Meters Biopharma, Inc. NASDAQ:NMTR, a clinical-stage biotechnology company focused on rare and unmet needs in gastroenterology, announced today that the United States Adopted Names USAN Council has officially designated the Companys long-acting injectable glucagon-like peptide-1 GLP-1 receptor agonist drug candidate for short bowel syndrome, NM-002, as vurolenatide. Unlike other agents in development for short bowel syndrome, vurolenatide is distinct not only from other GLP-1 agonists, but especially from GLP-2 agonists. 